Edwards Lifesciences (NYSE:EW) said that its board of directors authorized an additional $1 billion for stock repurchases, according to a recently posted SEC filing.
The Irvine, Calif.-based company said that with the additional allocation, it now has a total of $1.3 billion remaining under its share repurchase program.
In the same SEC filing, the company also said that it inked an accelerated share repurchase agreement for $150 million of its common stock, receiving approximately 672,000 shares.
The final number of shares is slated to be based on the volume-weighted average share price under the agreement, Edwards added.
Shares in Edwards are down 2.5% today at $176.87 as of 11:47 a.m. EDT.
Late last month, shares in Edwards fell slightly despite it posting Street-beating first quarter earnings results that saw the growth on the bottom line of over 20%.